Effects of Atorvastatin on Blood Pressure and Urinary Albumin Excretion

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the possible effects of atorvastatin on ambulatory blood pressure, urinary albumin excretion, insulin resistance and arterial stiffness in hypertensive patients, beyond those on lipid profile. Glycemic parameters, "novel" cardiovascular risk factors and safety parameters will be also evaluated.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pleiotropic Effects of Atorvastatin in High Cardiovascular Risk Patients

NCT01013103

Coronary Artery Disease HMG-CoA Reductase Inhibitor Toxicity Atherosclerosis +2 more

COMPLETED PHASE4

The Pleiotropic Effects of Atorvastatin When Combined With Common Antihypertenisve Medications.

NCT00656331

Hypertension

WITHDRAWN NA

Can Atorvastatin Improve Vascular Function in Women With a History of Preeclampsia?

NCT01278459

Pre-Eclampsia

COMPLETED PHASE3

Atorvastatin Study in Cardiovascular Disease Risk

NCT02392416

Hypercholesterolemia Dyslipidemia

COMPLETED

Acute Effect of HMG-CoA Reductase Inhibition (Atorvastatin)on Renal Hemodynamics, Tubular Function and Vasoactive Hormones on Healthy Subjects

NCT00344955

Healthy

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension Hypercholesterolemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Atorvastatin

Group Type ACTIVE_COMPARATOR

Atorvastatin

Intervention Type DRUG

10 mg of atorvastatin once daily for six months

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo once daily for six months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Atorvastatin

10 mg of atorvastatin once daily for six months

Intervention Type DRUG

Placebo

placebo once daily for six months

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* LDL-C\>130 or \>160 mg/dL (depending on the total risk according to the most recent recommendations25).
* no previous hypolipidemic medication
* ability to provide Informed Consent.

Exclusion Criteria

* pregnancy or lactation
* myocardial infarction or unstable angina within the past 6 months
* heart failure NYHA class III-IV
* renal disease (SCr\>3 mg/dL or proteinuria\>3g/d)
* liver disease
* history of malignancy
* history of drug or alcohol abuse
* treatment with corticosteroids
* any other condition with poor prognosis
* inability to provide Informed Consent.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No